These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28068599)

  • 1. Discovery of novel anti-angiogenesis agents. Part 6: Multi-targeted RTK inhibitors.
    Zhang L; Shan Y; Li C; Sun Y; Su P; Wang J; Li L; Pan X; Zhang J
    Eur J Med Chem; 2017 Feb; 127():275-285. PubMed ID: 28068599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
    Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
    Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents.
    Wang J; Zhang L; Pan X; Dai B; Sun Y; Li C; Zhang J
    Sci Rep; 2017 Mar; 7():45145. PubMed ID: 28332573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel anti-angiogenesis agents. Part 9: Multiplex inhibitors suppressing compensatory activations of RTKs.
    Shan Y; Si R; Wang J; Zhang Q; Zhou H; Song J; Zhang J; Chen Q
    Eur J Med Chem; 2019 Feb; 164():440-447. PubMed ID: 30616052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol.
    Pan X; Liang L; Si R; Wang J; Zhang Q; Zhou H; Zhang L; Zhang J
    Eur J Med Chem; 2019 Feb; 163():1-9. PubMed ID: 30503935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents.
    Zhang L; Shan Y; Ji X; Zhu M; Li C; Sun Y; Si R; Pan X; Wang J; Ma W; Dai B; Wang B; Zhang J
    Oncotarget; 2017 Dec; 8(62):104745-104760. PubMed ID: 29285210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biphenylurea/thiourea derivatives tagged with heteroarylsulfonamide motifs as novel VEGFR2 inhibitors; Design, synthesis and anti-angiogenic activity.
    Al-Ansary GH; Nasr T; Taha H; Fayad W; Mahgoub S
    Bioorg Chem; 2021 Feb; 107():104640. PubMed ID: 33485105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
    Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
    Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategies in achieving antiangiogenic effect: Multiplex inhibitors suppressing compensatory activations of RTKs.
    Shan Y; Wang B; Zhang J
    Med Res Rev; 2018 Sep; 38(5):1674-1705. PubMed ID: 29878411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
    Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
    Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
    Mitchell SA; Danca MD; Blomgren PA; Darrow JW; Currie KS; Kropf JE; Lee SH; Gallion SL; Xiong JM; Pippin DA; DeSimone RW; Brittelli DR; Eustice DC; Bourret A; Hill-Drzewi M; Maciejewski PM; Elkin LL
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6991-5. PubMed ID: 19879134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
    Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
    Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation.
    Zi M; Liu F; Wu D; Li K; Zhang D; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
    ChemMedChem; 2019 Jul; 14(13):1291-1302. PubMed ID: 31131561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
    Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
    Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
    Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL
    Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.
    Zhang X; Raghavan S; Ihnat M; Hamel E; Zammiello C; Bastian A; Mooberry SL; Gangjee A
    Bioorg Med Chem; 2015 May; 23(10):2408-23. PubMed ID: 25882519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach.
    Shan Y; Gao H; Shao X; Wang J; Pan X; Zhang J
    Eur J Med Chem; 2015 Oct; 103():80-90. PubMed ID: 26342134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents.
    Chen G; Weng Q; Fu L; Wang Z; Yu P; Liu Z; Li X; Zhang H; Liang G
    Bioorg Med Chem; 2014 Dec; 22(24):6953-60. PubMed ID: 25456085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.